Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Combo in Advanced Pancreatic Cancer
NCT04796948Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome in pancreatic cancer (PC), sponsored by Hengrui. Primary endpoints: Maximum Tolerated Dose at 18 months and Recommended Phase 2 Dose at 18 months. Started Apr 2021; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04796948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796948.